UBS AM
MREO

UBS AM’s Mereo BioPharma MREO Stock Holding History

UBS AM’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,763,666
Closed -$735K – 3841
2025
Q4 		$735K Sell
1,763,666
-143,109
-8% -$272K ﹤0.01% 2235
2025
Q3 		$3.93M Buy
+1,906,775
New +$3.52M ﹤0.01% 1480
2025
Q2 		– Sell
-1,569,100
Closed -$3.53M – 2686
2025
Q1 		$3.53M Buy
1,569,100
+604,200
+63% +$1.71M ﹤0.01% 1735
2024
Q4 		$3.38M Buy
+964,900
New +$3.79M ﹤0.01% 1794

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return

UBS AM's MREO Position: Q1 2026 in Review

UBS AM sold out of Mereo BioPharma (MREO) in Q1 2026, closing a stake of 1,763,666 shares — an estimated $735K sold.

UBS AM first reported a position in MREO in Q4 2024 and held it in 4 quarters. The position peaked at $3.93M in Q3 2025. 63 funds tracked by Wall St. Rank hold MREO as of Q1 2026.

  • UBS AM reported no remaining Mereo BioPharma position as of Q1 2026 after selling out during the quarter.
  • UBS AM sold 1,763,666 Mereo BioPharma shares in Q1 2026, an estimated $735K.
  • UBS AM first reported a position in Mereo BioPharma in Q4 2024 and held it in 4 quarters.
  • UBS AM's Mereo BioPharma position peaked at $3.93M in Q3 2025.
  • 63 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2026.

Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.